[MS Therapy Consensus Group. Immunomodulating staged therapy of multiple sclerosis].
The positive results of several multi-center studies significantly improved the immunomodulatory treatment of multiple sclerosis over the last few years. It was demonstrated that different compounds are capable to reduce the number of relapses and to modulate the progression of disease. To improve the transition of results obtained in these studies into daily clinical practice, a consensus group started to prepare a report on the current treatment options for the German-speaking European countries. The aim of this paper is to summarize the current knowledge, compare the results of recent clinical trials with the experience from other therapeutic options and assess their clinical evidence.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects; D005060:Europe; D006801:Humans; D007167:Immunotherapy; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects; D015337:Multicenter Studies as Topic; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a